Inhaled corticosteroid with short-acting β agonists or long-acting β agonist formoterol linked to reduction in exacerbations, improved control. HealthDay News — For patients with asthma, inhaled ...
Please provide your email address to receive an email when new articles are posted on . The meta-analysis included 27 unique randomized controlled trials and 50,496 patients. Combinations improved ...
AIRSUPRA® (albuterol/budesonide) represents a paradigm shift in asthma rescue as the first and only FDA-approved anti-inflammatory rescue inhaler for asthma that is designed to address both ...
Researchers had said that short-acting Beta-agonist (SABA) prescriptions could be used as a surrogate marker for asthma morbidity of steroid and non-steroid users. Using claims data for recipients ...
BOSTON -- Inhaled corticosteroids (ICS) combined either with formoterol (Foradil) or short-acting beta-agonists (SABA) for asthma treatment were associated with reduced risks of severe exacerbations ...
In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...
Please provide your email address to receive an email when new articles are posted on . Defined as three or more canisters a year, overuse of short-acting beta 2 agonists was associated with increased ...
The UK’s largest asthma study using real-world data has confirmed a link between over-reliance on SABA inhalers (short-acting beta-2 bronchodilators, also referred to as rescue inhalers) and an ...
Asthma is a common lung condition that affects 5.4 million people in the UK and can lead to symptoms such as coughing, wheezing or feeling breathless. Asthma is best controlled by regular use of a ...
Real-world evidence analysis of SABA use in over 1 million patients with asthma consistently showed three or more SABA inhalers a year was associated with increased risk of severe asthma exacerbations ...
Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs. Objective: To assess whether increased short-acting ...
New data shows overuse of SABA relievers is responsible for 250,000 tonnes of CO2 emissions annually New data has found that the overuse of short-acting beta2-agonist (SABA) relievers for asthma in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback